JP2021513540A5 - - Google Patents
Info
- Publication number
- JP2021513540A5 JP2021513540A5 JP2020542952A JP2020542952A JP2021513540A5 JP 2021513540 A5 JP2021513540 A5 JP 2021513540A5 JP 2020542952 A JP2020542952 A JP 2020542952A JP 2020542952 A JP2020542952 A JP 2020542952A JP 2021513540 A5 JP2021513540 A5 JP 2021513540A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000161A JP2024038250A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630038P | 2018-02-13 | 2018-02-13 | |
| US62/630,038 | 2018-02-13 | ||
| US201862732828P | 2018-09-18 | 2018-09-18 | |
| US62/732,828 | 2018-09-18 | ||
| US201862740741P | 2018-10-03 | 2018-10-03 | |
| US62/740,741 | 2018-10-03 | ||
| PCT/US2019/017188 WO2019160755A1 (en) | 2018-02-13 | 2019-02-08 | Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000161A Division JP2024038250A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021513540A JP2021513540A (ja) | 2021-05-27 |
| JP2021513540A5 true JP2021513540A5 (enExample) | 2022-09-08 |
Family
ID=67620098
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542952A Ceased JP2021513540A (ja) | 2018-02-13 | 2019-02-08 | 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
| JP2024000161A Withdrawn JP2024038250A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000161A Withdrawn JP2024038250A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210047409A1 (enExample) |
| EP (1) | EP3752193A4 (enExample) |
| JP (2) | JP2021513540A (enExample) |
| KR (1) | KR20200119845A (enExample) |
| CN (2) | CN119792515A (enExample) |
| AU (2) | AU2019222517A1 (enExample) |
| BR (1) | BR112020015915A8 (enExample) |
| CA (1) | CA3090996A1 (enExample) |
| MA (1) | MA51844A (enExample) |
| MX (1) | MX2020008446A (enExample) |
| WO (1) | WO2019160755A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| MA55316A (fr) * | 2019-03-13 | 2022-01-19 | Merck Sharp & Dohme | Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1 |
| CN113244385A (zh) * | 2020-02-07 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗恶性肿瘤中的用途 |
| JP2023515675A (ja) * | 2020-03-05 | 2023-04-13 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｐｄ－１アンタゴニスト、ｃｔｌａ４アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法 |
| WO2021178611A1 (en) * | 2020-03-05 | 2021-09-10 | Merck Sharp & Dohme Corp. | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-ctla4 antibody, and an anti-tigit antibody |
| WO2021213523A1 (zh) * | 2020-04-24 | 2021-10-28 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 |
| TW202305009A (zh) * | 2021-04-08 | 2023-02-01 | 美商默沙東有限責任公司 | 以皮下投予抗pd1抗體治療癌症之方法 |
| EP4373505A1 (en) * | 2021-07-19 | 2024-05-29 | Regeneron Pharmaceuticals, Inc. | Combination of checkpoint inhibitors and an oncolytic virus for treating cancer |
| MX2024004429A (es) * | 2021-10-29 | 2024-05-06 | Oncoc4 Inc | Regimenes de dosificacion del anticuerpo anti-ctla-4. |
| CN113933520B (zh) * | 2021-11-15 | 2023-06-20 | 邹灵龙 | 一种通用型抗体药血药浓度检测的单克隆抗体试剂组合、检测方法和试剂盒 |
| US20250376525A1 (en) * | 2022-06-28 | 2025-12-11 | Qilu Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof |
| AU2023338559A1 (en) * | 2022-09-09 | 2025-03-27 | Adagene Pte. Ltd. | Activatable anti-ctla4 antibodies for treating cancer |
| CN118767127A (zh) * | 2023-04-10 | 2024-10-15 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体的医药用途 |
| KR20260056175A (ko) * | 2023-08-21 | 2026-04-24 | 아게누스 인코포레이티드 | Ctla-4 저해제와 pd-1 저해제의 병용을 이용한 결장직장암의 치료 방법 |
| TW202511295A (zh) * | 2023-08-31 | 2025-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｃｔｌａ４／ｔｉｇｉｔ結合蛋白及其醫藥用途 |
| WO2026021409A1 (zh) * | 2024-07-22 | 2026-01-29 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向ctla-4、pd-l1和vegf的肿瘤联合疗法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ517202A (en) * | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) * | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| US10695426B2 (en) * | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
| EP3288980B1 (en) * | 2015-04-28 | 2021-03-10 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| DK3858859T3 (da) * | 2015-07-14 | 2025-12-15 | Bristol Myers Squibb Co | Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1) |
| WO2017021911A1 (en) * | 2015-08-04 | 2017-02-09 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| EP3331919A1 (en) * | 2015-08-07 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
| CN108495651A (zh) * | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| EP3213768A1 (en) * | 2016-03-01 | 2017-09-06 | LODOCO CLINICAL Kft | Combination of low dose immune checkpoint blockade with high dose il-2 for treating metastatic cancer |
| HUE062398T2 (hu) * | 2016-06-02 | 2023-10-28 | Bristol Myers Squibb Co | PD-1 blokád nivolumabbal refrakter Hodgkin limfómában |
| KR20250107295A (ko) * | 2016-06-03 | 2025-07-11 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체 |
| KR102976378B1 (ko) * | 2016-06-03 | 2026-06-11 | 브리스톨-마이어스 스큅 컴퍼니 | 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도 |
| CA3060695A1 (en) * | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
-
2019
- 2019-02-08 CN CN202510115562.9A patent/CN119792515A/zh active Pending
- 2019-02-08 KR KR1020207026005A patent/KR20200119845A/ko not_active Withdrawn
- 2019-02-08 MA MA051844A patent/MA51844A/fr unknown
- 2019-02-08 CA CA3090996A patent/CA3090996A1/en active Pending
- 2019-02-08 EP EP19754385.3A patent/EP3752193A4/en active Pending
- 2019-02-08 US US16/966,988 patent/US20210047409A1/en active Pending
- 2019-02-08 JP JP2020542952A patent/JP2021513540A/ja not_active Ceased
- 2019-02-08 MX MX2020008446A patent/MX2020008446A/es unknown
- 2019-02-08 WO PCT/US2019/017188 patent/WO2019160755A1/en not_active Ceased
- 2019-02-08 AU AU2019222517A patent/AU2019222517A1/en not_active Abandoned
- 2019-02-08 CN CN201980013384.1A patent/CN111727056A/zh active Pending
- 2019-02-08 BR BR112020015915A patent/BR112020015915A8/pt not_active Application Discontinuation
-
2023
- 2023-07-26 AU AU2023208115A patent/AU2023208115A1/en active Pending
-
2024
- 2024-01-04 JP JP2024000161A patent/JP2024038250A/ja not_active Withdrawn